Successful and safe treatment of hemangioma with oral propranolol in a single institution / 소아과
Korean Journal of Pediatrics
;
: 164-170, 2012.
Article
in English
| WPRIM
| ID: wpr-56891
ABSTRACT
PURPOSE:
Dramatic improvement of hemangioma to propranolol has been recently reported; however, details on dose and duration of treatment, potential risks, and monitoring have not been determined. The objective of this study is to describe and analyze the use of propranolol as a first-line treatment or as a single therapy in management of complicated hemangioma.METHODS:
A retrospective chart review of eight patients diagnosed with hemangioma and treated with propranolol in Kangbuk Samsung Hospital from February 2010 to April 2011 was performed.RESULTS:
Eight patients with hemangioma with functional impairment, cosmetic disfigurement, or rapid growth were treated with propranolol. Five patients had solitary facial hemangioma. The mean age of symptoms at onset was 5 weeks. The median age for starting propranolol treatment was 5.5 months. Propranolol at 2 mg/kg/day was finally administered in divided doses with a gradual increase. Significant regression was observed in seven patients, and shrinkage in size, softening in consistency, and decrease in redness were evident within 4 weeks. Among them, six patients were still taking propranolol, and one patient had stopped after 12 months. Other one patient did not show significant improvement with satisfactory result after 3 months of propranolol use. Treatment with propranolol was well tolerated and had few side effects. No rebound growth was observed in any of the patients.CONCLUSION:
We observed that use of propranolol was very effective in treatment of hemangioma without obvious adverse effects or relapse.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Propranolol
/
Recurrence
/
Retrospective Studies
/
Cosmetics
/
Hemangioma
Type of study:
Observational study
Limits:
Humans
Language:
English
Journal:
Korean Journal of Pediatrics
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS